<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132971">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112578</url>
  </required_header>
  <id_info>
    <org_study_id>APS 002/2013</org_study_id>
    <secondary_id>BRA13APS002-2014</secondary_id>
    <secondary_id>U1111-1149-6768</secondary_id>
    <nct_id>NCT02112578</nct_id>
  </id_info>
  <brief_title>Eficacy and Tolerability of MECLIN® (Meclizine Chlorhydrate) in Acute Vertigo and Manifestations Neurovegetative</brief_title>
  <official_title>Eficacy and Tolerability of MECLIN® (Meclizine Chlorhydrate) in Acute Vertigo and Manifestations Neurovegetative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apsen Farmaceutica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apsen Farmaceutica S.A.</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Evaluation of the efficacy and tolerability of Meclin (meclizine) versus Dramin
           (Dimenhydrinate) to treat the symptoms of vertigo;

        -  Evaluation of impact on quality of life in vertigo;

        -  Evaluation of drowsiness caused by antihistamines used in the study;

        -  Adverse event;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study duration will be 15 days (visit 1, visit 2, and visit 3);

        -  Symptoms of vertigo will be assessed at every visit, through a daily participant in the
           study report the intensity of their symptoms and outcome.

        -  Goal is the acquisition of data as proportion of participants with MVS= 0.5 considered
           treatment responders, and proportion of patients with symptoms higher percentage
           reduction of 50%
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Media Vertigo score (MVS)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of efficacy by varying the Media Vertigo score (MVS) which is the average of the intensities of vertigo symptoms described at Visit 1, assigning the scores to 0-4 categories None, Mild, Moderate, Strong, Very Strong, respectively. The primary hypothesis is the non-inferiority of Meclizine chlorhydrate regarding Dimenidrinato in reducing the MVS V1 to V2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dizziness Handicap Inventory (Brazilian version)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of impact of dizziness on quality of life DHI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stanford Sleepiness and Epworth</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of somnolence (baseline measurement)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vertigo</condition>
  <condition>Vestibular Disease</condition>
  <arm_group>
    <arm_group_label>Meclizine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meclizine 25 mg, tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimenhydrinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dimenhydrinate 50 mg, soft Capsgel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meclizine</intervention_name>
    <description>25 mg, 3 times per day for 15 days</description>
    <arm_group_label>Meclizine</arm_group_label>
    <other_name>Meclin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimenhydrinate</intervention_name>
    <description>50 mg, 3 times per day for 15 days</description>
    <arm_group_label>Dimenhydrinate</arm_group_label>
    <other_name>Dramin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Woman aged above 18 years;

          -  Presence of dizziness / vertigo of vestibular origin symptons , and / or
             neurovegetative manifestations due to peripheral vestibular disorders;

          -  Participant with dizziness / vertigo of vestibular origin symptoms, show moderate
             intensity on in 5-points Likert scale of: absent, mild , moderate , severe and very
             severe;

          -  Woman with negative Beta hcg;

          -  Participants who present normal or controlled blood pressure;

        Exclusion Criteria:

          -  Used meclizine or dimenidrynate in 15 days;

          -  Used alcohol in 48 hours;

          -  Pregnancy or breastfeeding;

          -  Presence of vomiting which prevent the ingestion of tablets ;

          -  Presence of clinical condition that determines contraindication to the active
             substances : convulsions , suspected intracranial compressive processes ,
             closed-angle glaucoma , prostatic adenoma with urinary disorders , liver diseases ,
             endocrine , renal, and / or uncontrolled cardiovascular , Parkinson's disease;

          -  Participants with bladder neck obstruction or symptomatic prostatic hyperplasia :
             anticholinergic effects of Meclizine may precipitate urinary retention;

          -  a known sensitivity to hydrochloride, meclizine or dimenhydrinate;

          -  Presence of malignant carcinomas or not remitted for more than 5 years;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Ganança, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristiane Lima</last_name>
    <phone>55 11 5644-8200</phone>
    <phone_ext>8269</phone_ext>
    <email>cristiane.lima@apsen.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>IPO - Parana Otorhinolaryngology Institute</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80610-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Gasperin, MD</last_name>
      <phone>55 41 3094-5751</phone>
    </contact>
    <investigator>
      <last_name>Alexandre Gasperin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Otorhinolaryngology Department of Federal University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-032</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Ganança, PhD</last_name>
      <phone>55115539-5378</phone>
    </contact>
    <investigator>
      <last_name>Fernando Ganança, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vertigo, Meclizine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
    <mesh_term>Vestibular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meclizine</mesh_term>
    <mesh_term>Dimenhydrinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
